摘要
目的观察依那西普与柳氮磺吡啶治疗强直性脊柱炎的效果。方法入选2013年3~11月新疆医科大学附属中医医院风湿科40例活动性强直性脊柱炎患者,随机分为依那西普组和柳氮磺吡啶组,每组各20例,分别给予依那西普（每周2次,每次25 mg）及柳氮磺吡啶（每天2次,每次1.0 g）治疗,共治疗12周,比较两组治疗后的效果,并比较两组治疗前后外周血中肿瘤坏死因子α、C反应蛋白、血沉的水平。结果治疗12周后,柳氮磺吡啶组的总有效率为70%,依那西普组的总有效率为95%,两组比较差异有统计学意义（P〈0.05）;依那西普组在降低强直性脊柱炎患者血清中肿瘤坏死因子α水平上优于柳氮磺吡啶组（P〈0.01）,在降低C反应蛋白方面优于柳氮磺吡啶组（P=0.012）,在降低血沉方面优于柳氮磺吡啶组（P=0.002）。结论依那西普治疗强直性脊柱炎的效果明显优于柳氮磺吡啶,依那西普可显著改善患者肿瘤坏死因子α、C反应蛋白、血沉等指标。
Objective To observe the efficacy of Etanercept and Sulfasalazine in the treatment of ankylosing spondylitis.Methods Forty cases of patients with active ankylosing spondylitis were selected in Department of Rheumatology,Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine, from March to November 2013, and they were divided into Etanercept group and Sulfasalazine group, with 20 cases in each group. They were given Etanercept（twice a week, 25 mg/time） and Sulfasalazine（twice a day, 1.0 g/time） respectively for 12 weeks. The efficacy of the two groups after treatment was compared, and the levels of tumor necrosis factor α, C-reactive protein and erythrocyte sedimentation rate before and after treatment were compared. Results After 12 weeks, the total effective rate of Sulfasalazine group was 70%, which of the Etanercept group was 95%, there was a statistically significant difference（P〈0.05）. Etanercept group in reducing tumor necrosis factor-α in patients with ankylosing spondylitis was superior to Sulfasalazine group（P〈0.01）; Etanercept group in reducing C-reactive protein was superior to Sulfasalazine group（P =0.012）; Etanercept group in reducing erythrocyte sedimentation rate was superior to Sulfasalazine group（P = 0.002）.Conclusion The efficacy of Etanercept is better than Sulfasalazine in treatment of ankylosing spondylitis, and the Etanercept can reduce the level of tumor necrosis factor α, C-reactive protein and erythrocyte sedimentation rate.
出处
《中国医药导报》
CAS
2015年第7期82-85,共4页
China Medical Herald
